Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 29;12(11):1788.
doi: 10.3390/jpm12111788.

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update

Alessandro Rizzo  1 , Angela Dalia Ricci  2 , Giovanni Brandi  3   4
Affiliations

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update

Alessandro Rizzo et al. J Pers Med. .

Abstract

Recent years have seen the advent of novel treatment options for hepatocellular carcinoma (HCC). Given a strong biological rationale supporting this strategy, multiple studies have explored the role of combination treatments including locoregional plus systemic therapies to produce a synergistic effect and enhance antitumor activity. Among locoregional therapies, several clinical trials assessing trans-arterial chemoembolization (TACE) have been recently presented and published. In the current paper, we discuss available evidence and current and future research on combined TACE and systemic treatments, including antiangiogenic agents, immune checkpoint inhibitors, and immune-based combinations for HCC patients.

Keywords: TACE; hepatocellular carcinoma; immunotherapy; locoregional therapies; systemic treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Llovet J.M., Castet F., Heikenwalder M., Maini M.K., Mazzaferro V., Pinato D.J., Pikarsky E., Zhu A.X., Finn R.S. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 2021;19:151–172. doi: 10.1038/s41571-021-00573-2. - DOI - PubMed
    1. Rizzo A., Ricci A.D., Gadaleta-Caldarola G., Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: Current management and future challenges. Expert Rev. Gastroenterol. Hepatol. 2021;15:1245–1251. doi: 10.1080/17474124.2021.1973431. - DOI - PubMed
    1. Manjunatha N., Ganduri V., Rajasekaran K., Duraiyarasan S., Adefuye M. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus. 2022;14:e28439. doi: 10.7759/cureus.28439. - DOI - PMC - PubMed
    1. Yang X.-G., Sun Y.-Y., Wang H.-Q., Li D.-S., Xu G.-H., Huang X.-Q. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Front. Oncol. 2022;12:914385. doi: 10.3389/fonc.2022.914385. - DOI - PMC - PubMed
    1. Sangro B., Sarobe P., Hervás-Stubbs S., Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2021;18:525–543. doi: 10.1038/s41575-021-00438-0. - DOI - PMC - PubMed

LinkOut - more resources